跳至主要内容
临床试验/EUCTR2014-001088-11-BE
EUCTR2014-001088-11-BE进行中(未招募)不适用

Academic study on the effects of MP 29-02 nasal spray on inflammatory mediators in allergic rhinitis

MEDA0 个研究点开始时间: 2014年3月21日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
MEDA

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Patients with an ARIA-based diagnosis of persistent moderate/severe AR (= 2 nasal symptoms suggestive of allergic rhinitis and positive skin prick tests to HDM (HAL Allergy, Leiden, The Netherlands) at screening. Patients with additional seasonal pollen allergies may be included providing that they are included outside their individual pollen season, and with VAS score for total nasal symptoms of more than 5
  • 2.VAS for TNS of more than 5, and rT5SS of more than 8 at both screening and randomization
  • 3.Age > 18 and < 60 years
  • 4.Eosinophilia of more than 5% in nasal secretions at screening
  • 5.Nasal hyperreactivity (drop of PNIF >20 %) at randomization
  • 6.Possibility to give reliable information and written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 45
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Any evidence of clinically relevant acute or chronic cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, metabolic, mental, neurological, or other disease at screening
  • 2.History of allergic reaction to fluticasone propionate, azelastine hydrochloride or one of the excipients (e.g. benzalkonium chloride, phenylethyl alcohol, microcrystalline cellulose)
  • 3.Patients with a change in vision or with a history of increased ocular pressure, glaucoma and/or cataracts
  • 4.Patients with tuberculosis, any type of untreated infection, or recent surgical operation or injury to the nose or mouth
  • 5.Patients with moderate persistent to severe persistent asthma according to GINA criteria (9)
  • 6.Patients on prolonged use of decongestive nose sprays, suffering from so-called rhinitis medicamentosa
  • 7.Patients using other nasal or oral medication affecting nasal function, like nasal corticosteroids, anticholinergics, cromoglycates, leukotriene antagonists, ACE inhibitors during the study or within the last 14 days before randomization; patients using oral corticosteroids during the last 30 days
  • 8.Patients using cytochrome P450 3A4 inhibitors (e.g. ritonavir)
  • 9.Nasal endoscopic evidence of rhinosinusitis w/wo NP or structural abnormalities such as clinically relevant septal deviation (septum reaching concha inferior or lateral nasal wall) or septal perforation at screening
  • 10.Patients on immunotherapy (IT) for HDM or with history of IT for HDM
  • 11.Patients with a psychiatric, addictive, or any disorder of which the investigators feel that this may compromise the ability to give truly informed consent for participation in this study or provide reliable information on the questionnaire
  • 12.Patients being enrolled in other clinical trials within the last 3 months
  • 13.Pregnancy or breastfeeding
  • 14.Malignancies or severe comorbidity
  • 15.Smoking
  • 16.Use of anticoagulation medication

研究者

发起方
MEDA

相似试验